Srinivasa Rao M, Rao Sumathi V, Srinivasa Rao D V N, Bharathi Ch, Rajput Pradeep, Sharma Hemant Kumar
APL Research Centre, Hyderabad, India.
Pharmazie. 2010 May;65(5):336-8.
Rivastigmine is a drug against Alzheimer's disease, and is a non-pharmacopoeial compound. During the preparation of rivastigmine in our laboratory, two impurities were detected and identified with a simple and sensitive reversed-phase liquid chromatography coupled with electrospray-mass spectrometry. The same impurities were also observed in commercial batches. These impurities were isolated by preparative HPLC and co-injected with rivastigmine sample to confirm the retention times in HPLC. These impurities were characterized as N,N-dimethyl-3-[1-dimethylaminoethyl]phenylcarboxylate (dimethyl-rivastigmine) and N,N-diethyl-3-[1-dimethylaminoethyl]phenylcarboxamide (diethyl-rivastigmine). Structural elucidation of these impurities by spectral data (1H NMR, 13C NMR and MS) is discussed.
卡巴拉汀是一种治疗阿尔茨海默病的药物,是一种非药典化合物。在我们实验室制备卡巴拉汀的过程中,通过简单灵敏的反相液相色谱-电喷雾质谱联用技术检测并鉴定出了两种杂质。在市售批次中也观察到了同样的杂质。通过制备型高效液相色谱法分离出这些杂质,并与卡巴拉汀样品共注入以确认其在高效液相色谱中的保留时间。这些杂质被鉴定为N,N-二甲基-3-[1-二甲基氨基乙基]苯基羧酸酯(二甲基卡巴拉汀)和N,N-二乙基-3-[1-二甲基氨基乙基]苯基甲酰胺(二乙基卡巴拉汀)。讨论了通过光谱数据(1H NMR、13C NMR和MS)对这些杂质进行结构解析的情况。